Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer

Journal Article · · PLoS Pathogens
 [1];  [2];  [3];  [4];  [2];  [5];  [5];  [5];  [2];  [2];  [6];  [2]
  1. La Jolla Institute for Allergy and Immunology, CA (United States); OSTI
  2. La Jolla Institute for Allergy and Immunology, CA (United States)
  3. University of Texas Health Science Center, San Antonio, TX (United States)
  4. University of Seville (Spain)
  5. Saint Louis University School of Medicine, MO (United States)
  6. University of Texas Health Science Center, San Antonio, TX (United States)
Vaccinia virus A33 is an extracellular enveloped virus (EEV)-specific type II membrane glycoprotein that is essential for efficient EEV formation and long-range viral spread within the host. A33 is a target for neutralizing antibody responses against EEV. In this study, we produced seven murine anti-A33 monoclonal antibodies (MAbs) by immunizing mice with live VACV, followed by boosting with the soluble A33 homodimeric ectodomain. Five A33 specific MAbs were capable of neutralizing EEV in the presence of complement. All MAbs bind to conformational epitopes on A33 but not to linear peptides. To identify the epitopes, we have adetermined the crystal structures of three representative neutralizing MAbs in complex with A33. We have further determined the binding kinetics for each of the three antibodies to wild-type A33, as well as to engineered A33 that contained single alanine substitutions within the epitopes of the three crystallized antibodies. While the Fab of both MAbs A2C7 and A20G2 binds to a single A33 subunit, the Fab from MAb A27D7 binds to both A33 subunits simultaneously. A27D7 binding is resistant to single alanine substitutions within the A33 epitope. A27D7 also demonstrated high-affinity binding with recombinant A33 protein that mimics other orthopoxvirus strains in the A27D7 epitope, such as ectromelia, monkeypox, and cowpox virus, suggesting that A27D7 is a potent cross-neutralizer. Finally, we confirmed that A27D7 protects mice against a lethal challenge with ectromelia virus.
Research Organization:
SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States). Stanford Synchrotron Radiation Lightsource (SSRL)
Sponsoring Organization:
National Institute of General Medical Sciences (NIGMS); National Institutes of Health (NIH); USDOE Office of Science (SC), Biological and Environmental Research (BER)
Grant/Contract Number:
AC02-76SF00515
OSTI ID:
1903993
Journal Information:
PLoS Pathogens, Journal Name: PLoS Pathogens Journal Issue: 9 Vol. 11; ISSN 1553-7374
Publisher:
Public Library of ScienceCopyright Statement
Country of Publication:
United States
Language:
English

References (92)

Proteome-wide analysis of the serological response to vaccinia and smallpox journal May 2007
Shape Complementarity at Protein/Protein Interfaces journal December 1993
A Myristylated Membrane Protein Encoded by the Vaccinia Virus L1R Open Reading Frame Is the Target of Potent Neutralizing Monoclonal Antibodies journal August 1995
Neutralizing and Protective Antibodies Directed against Vaccinia Virus Envelope Antigens journal February 1999
The Vaccinia Virus A36R Protein Is a Type Ib Membrane Protein Present on Intracellular but Not Extracellular Enveloped Virus Particles journal May 2000
Generation and Characterization of Monoclonal Antibodies Specific for Vaccinia Virus book January 2012
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope journal June 1992
Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge journal September 2004
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination journal February 2008
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE® journal February 2010
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge journal September 2010
Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens journal February 2008
There is an A33-dependent mechanism for the incorporation of B5-GFP into vaccinia virus extracellular enveloped virions journal June 2010
The inability of vaccinia virus A33R protein to form intermolecular disulfide-bonded homodimers does not affect the production of infectious extracellular virus journal December 2010
Generation and characterization of a large panel of murine monoclonal antibodies against vaccinia virus journal January 2011
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination journal November 2006
Principles of protein-protein interactions. journal January 1996
A Reality in Our Time--Certification of the Global Eradication of Smallpox journal October 1980
Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox Challenge journal January 2011
The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface journal January 2002
Phaser crystallographic software journal July 2007
A statistic for local intensity differences: robustness to anisotropy and pseudo-centering and utility for detecting twinning journal June 2003
MolProbity : all-atom structure validation for macromolecular crystallography journal December 2009
Features and development of Coot journal March 2010
iMOSFLM : a new graphical interface for diffraction-image processing with MOSFLM journal March 2011
The CCP4 suite programs for protein crystallography journal September 1994
Structural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5 journal May 2012
Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model journal September 2007
Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein journal July 2014
Vaccination of BALB/c Mice with Escherichia coli -Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge journal April 2008
Unusual Features of Vaccinia Virus Extracellular Virion Form Neutralization Resistance Revealed in Human Antibody Responses to the Smallpox Vaccine journal February 2013
Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine journal January 2008
The Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like Domains journal March 2010
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus journal November 1985
Vaccinia virus gene D8 encodes a virion transmembrane protein journal October 1988
The Envelope Protein Encoded by the A33R Gene Is Required for Formation of Actin-Containing Microvilli and Efficient Cell-to-Cell Spread of Vaccinia Virus journal May 1998
Vaccinia Virus Envelope H3L Protein Binds to Cell Surface Heparan Sulfate and Is Important for Intracellular Mature Virion Morphogenesis and Virus Infection In Vitro and In Vivo journal April 2000
Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions journal October 2004
Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus journal June 2005
Vaccinia Virus H3L Envelope Protein Is a Major Target of Neutralizing Antibodies in Humans and Elicits Protection against Lethal Challenge in Mice journal August 2005
Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge journal November 2005
Antibody-Antigen Complexes journal June 1990
Necrotic Ulcerated Lesion in a Young Boy Caused by Cowpox Virus Infection journal January 2011
Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response journal July 2013
Antibody against Extracellular Vaccinia Virus (EV) Protects Mice through Complement and Fc Receptors journal June 2011
Emergence of Cowpox: Study of the Virulence of Clinical Strains and Evaluation of Antivirals journal February 2013
An Increasing Danger of Zoonotic Orthopoxvirus Infections journal December 2013
Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge journal March 2010
Deaths Attributable to Smallpox Vaccination, 1959 to 1966, and 1968 journal April 1970
Role for the Vaccinia Virus A36R Outer Envelope Protein in the Formation of Virus-Tipped Actin-Containing Microvilli and Cell-to-Cell Virus Spread journal April 1998
Characterization of vaccinia virus glycoproteins by monoclonal antibody precipitation journal March 1992
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope journal June 1992
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates journal February 2003
Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial journal January 2005
Cloning and expression of murine Ig genes from single B cells journal October 2009
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein journal November 2007
Clonal vaccinia virus grown in cell culture as a new smallpox vaccine journal August 2003
Duration of antiviral immunity after smallpox vaccination journal August 2003
IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis journal May 2008
Phaser crystallographic software journal July 2007
A statistic for local intensity differences: robustness to anisotropy and pseudo-centering and utility for detecting twinning journal June 2003
MolProbity : all-atom structure validation for macromolecular crystallography journal December 2009
Features and development of Coot journal March 2010
An introduction to data reduction: space-group determination, scaling and intensity statistics journal March 2011
iMOSFLM : a new graphical interface for diffraction-image processing with MOSFLM journal March 2011
Structural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5 journal May 2012
Characterization of Chimpanzee/Human Monoclonal Antibodies to Vaccinia Virus A33 Glycoprotein and Its Variola Virus Homolog In Vitro and in a Vaccinia Virus Mouse Protection Model journal September 2007
Vaccinia Virus F9 Virion Membrane Protein Is Required for Entry but Not Virus Assembly, in Contrast to the Related L1 Protein journal October 2006
Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein journal July 2014
Heavily Isotype-Dependent Protective Activities of Human Antibodies against Vaccinia Virus Extracellular Virion Antigen B5 journal September 2009
Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on Complement journal February 2009
Vaccination of BALB/c Mice with Escherichia coli -Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge journal April 2008
Unusual Features of Vaccinia Virus Extracellular Virion Form Neutralization Resistance Revealed in Human Antibody Responses to the Smallpox Vaccine journal February 2013
Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox Vaccine journal January 2008
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus journal November 1985
Vaccinia virus gene D8 encodes a virion transmembrane protein journal October 1988
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope journal December 1992
Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress journal March 1992
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene journal June 1996
The Envelope Protein Encoded by the A33R Gene Is Required for Formation of Actin-Containing Microvilli and Efficient Cell-to-Cell Spread of Vaccinia Virus journal May 1998
Vaccinia Virus Envelope H3L Protein Binds to Cell Surface Heparan Sulfate and Is Important for Intracellular Mature Virion Morphogenesis and Virus Infection In Vitro and In Vivo journal April 2000
The Vaccinia Virus A33R Protein Provides a Chaperone Function for Viral Membrane Localization and Tyrosine Phosphorylation of the A36R Protein journal January 2001
Protective Immunity to Vaccinia Virus Induced by Vaccination with Multiple Recombinant Outer Membrane Proteins of Intracellular and Extracellular Virions journal October 2004
Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus journal June 2005
Vaccinia Virus H3L Envelope Protein Is a Major Target of Neutralizing Antibodies in Humans and Elicits Protection against Lethal Challenge in Mice journal August 2005
Combinations of Polyclonal or Monoclonal Antibodies to Proteins of the Outer Membranes of the Two Infectious Forms of Vaccinia Virus Protect Mice against a Lethal Respiratory Challenge journal November 2005
Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response journal July 2013
The strategic use of novel smallpox vaccines in the post-eradication world journal July 2011
Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. journal November 2005
Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model journal January 2010
Protective Murine and Human Monoclonal Antibodies against Eczema Vaccinatum journal January 2011
Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination journal November 2003